# Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Luca Gianni,W. Eiermann,Semiglazov Vf,Alexey Manikhas,Aňa Lluch,S. Tjulandin,Milvia Zambetti,Federico Vázquez,Mikhail Byakhow,Mikhail Lichinitser,Miguel Ángel Climent,Eva Ciruelos,B. Ojeda,Mauro Mansutti,А. А. Божок,Roberta Baronio,A. Feyereislova,Claire Barton,Pinuccia Valagussa,José Baselga |
| Citations | 1,270 |
| DOI | 10.1016/s0140-6736(09)61964-4 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1987326983 |
| PMID | 20113825 |
| Type | article |
| Year | 2010 |

## Paper authors

- [W. Eiermann](https://scholariq.org/researchers/w-eiermann/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.